title: Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model.
abstract: We evaluated the effect of tamoxifen (TAM) on tumor development in proto-neu transgenic mice that spontaneously develop mammary carcinomas overexpressing the neu protein. These mammary carcinomas are hormone independent because superimposable growth of transplants was observed in females and males. Virgin transgenic mice treated with TAM from 24 weeks of age, ie., when subclinical mammary tumors are already present, showed a slightly accelerated tumor development. In contrast, transgenic mice treated with TAM starting at 12 weeks of age, when subclinical tumors are not yet present, showed a 50% reduction of tumor incidence. Light microscopy analysis of the mammary gland of these mice revealed an apparently normal ductal branching but a complete regression of the acini. In conclusion, TAM can prevent the occurrence of hormone-independent breast carcinoma if given early enough to inhibit normal cells.
authors.affiliation: Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy. menard@istitutotumori.mi.it
authors.forename: S
authors.initials: S
authors.lastname: Ménard
authors.forename: P
authors.initials: P
authors.lastname: Aiello
authors.forename: E
authors.initials: E
authors.lastname: Tagliabue
authors.forename: C
authors.initials: C
authors.lastname: Rumio
authors.forename: P L
authors.initials: PL
authors.lastname: Lollini
authors.forename: M I
authors.initials: MI
authors.lastname: Colnaghi
authors.forename: A
authors.initials: A
authors.lastname: Balsari
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D005260:Female; D018734:Genes, erbB-2; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000473:pathology / Q000517:prevention & control*; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D011401:Promoter Regions, Genetic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D016588:Anticarcinogenic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen